A Central Role for Monocyte-Platelet Interactions in Heart Failure (Q38620927)

4 September 2017

A Central Role for Monocyte-Platelet Interactions in Heart Failure (English)

1 reference

4 September 2017

0 references

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26519384%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

author name string

Nadezhda Glezeva

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26519384%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

John F Gilmer

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26519384%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Chris J Watson

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26519384%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

publication date

30 October 2015

1 reference

Journal of Cardiovascular Pharmacology and Therapeutics

4 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26519384%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26519384%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26519384%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

page(s)

245-261

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26519384%20AND%20SRC:MED&resulttype=core&format=json

Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups

6 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Heart disease and stroke statistics--2014 update: a report from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Life expectancy for community-based patients with heart failure from time of diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

New insights in (inter)cellular mechanisms by heart failure with preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Endocardial endothelial dysfunction and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

The cardiovascular continuum refined: A hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Hypertension as an underlying factor in heart failure with preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Inflammation and metabolic dysfunction: links to cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Type 2 diabetes as an inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Impaired endothelium-dependent regulation of ventricular relaxation in pressure-overload cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Systemic inflammation in heart failure--the whys and wherefores

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

A glossary of circulating cytokines in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Targeted anticytokine therapy and the failing heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Innate immunity and the failing heart: the cytokine hypothesis revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Anti-inflammatory therapies for cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Impact of aspirin and statins on long-term survival in patients hospitalized with acute myocardial infarction complicated by heart failure: an analysis of 1706 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Enhancement of the endothelial NO synthase attenuates experimental diastolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

The nitric oxide donor pentaerythritol tetranitrate reduces platelet activation in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

AVE3085, an enhancer of endothelial nitric oxide synthase, restores endothelial function and reduces blood pressure in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

The eNOS enhancer AVE 9488: a novel cardioprotectant against ischemia reperfusion injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Endothelial targeting of nanocarriers loaded with antioxidant enzymes for protection against vascular oxidative stress and inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Inhibition of platelet activation by clopidogrel prevents hypertension-induced cardiac inflammation and fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

The direct factor Xa inhibitor Rivaroxaban reduces platelet activation in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Warfarin and aspirin in patients with heart failure and sinus rhythm

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Involvement of monocytes/macrophages as key factors in the development and progression of cardiovascular diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Platelets as cellular effectors of inflammation in vascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Platelets and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

The prognostic value of circulating soluble cell adhesion molecules in patients with chronic congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Soluble CD40 ligand in acute and chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Soluble, platelet-bound, and total P-selectin as indices of platelet activation in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Evaluation of platelets in heart failure: is platelet activity related to etiology, functional class, or clinical outcomes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Clinical utility of the platelet function analyzer (PFA-100) for the assessment of the platelet status in patients with congestive heart failure (EPCOT trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Monocytes in coronary artery disease and atherosclerosis: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

The origin and kinetics of mononuclear phagocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Extramedullary hematopoiesis generates Ly-6C(high) monocytes that infiltrate atherosclerotic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Rapid monocyte kinetics in acute myocardial infarction are sustained by extramedullary monocytopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Monocytes in heart failure: relationship to a deteriorating immune overreaction or a desperate attempt for tissue repair?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

The role of monocytes and inflammation in the pathophysiology of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Characterization of the inflammatory and fibrotic response in a mouse model of cardiac pressure overload.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Endogenous mechanisms of inhibition of platelet function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Platelet activation and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Cell adhesion mechanisms in platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Central role of the P2Y12 receptor in platelet activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Antiplatelet and antithrombin strategies in acute coronary syndrome: state-of-the-art review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Prostanoid receptors. Structure, function, and distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Antiplatelet therapy: targeting the TxA2 pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Thromboxane Antagonism with terutroban in Peripheral Arterial Disease: the TAIPAD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Protease-activated receptors in hemostasis, thrombosis and vascular biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Bivalirudin for patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Bivalirudin during primary PCI in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Comparison of fondaparinux and enoxaparin in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Rivaroxaban in patients with a recent acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Apixaban with antiplatelet therapy after acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Vorapaxar in the secondary prevention of atherothrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Monocyte and macrophage heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

How dying cells alert the immune system to danger

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

The role of monocytes in atherosclerotic coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction:a possible role for left ventricular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Increased formation of monocyte-platelet aggregates in ischemic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Platelet binding to monocytes increases the adhesive properties of monocytes by up-regulating the expression and functionality of beta1 and beta2 integrins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Platelets in inflammation and atherogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

The chemokine system in diverse forms of macrophage activation and polarization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Macrophage plasticity and polarization: in vivo veritas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Course of platelet activation and platelet-leukocyte interaction in cerebrovascular ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Platelet function following acute cerebral ischemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Platelet degranulation and monocyte-platelet complex formation are increased in the acute and convalescent phases after ischaemic stroke or transient ischaemic attack.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Increased platelet reactivity is associated with circulating platelet-monocyte complexes and macrophages in human atherosclerotic plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Decreased platelet nitric oxide contributes to increased circulating monocyte-platelet aggregates in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Monocyte-platelet interaction induces a pro-inflammatory phenotype in circulating monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Platelet-leukocyte cross talk in whole blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Renal effects of aspirin are clearly dose-dependent and are of clinical importance from a dose of 160 mg.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Differential inhibition of tumour cell-induced platelet aggregation by the nicotinate aspirin prodrug (ST0702) and aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Collagen remodeling of the pressure-overloaded, hypertrophied nonhuman primate myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Matrix gene expression and decompensated heart failure: the aged SHR model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Coronary perivascular fibrosis is associated with impairment of coronary blood flow in patients with non-ischemic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Plasma P-selectin predicts long-term cardiovascular events in hospitalized patients with suspected coronary artery disease and preserved left ventricular function: a 10-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Exercise training decreases plasma levels of soluble CD40 ligand and P-selectin in patients with chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Does heart failure etiology, New York Heart Association class, or ejection fraction affect the ability of clopidogrel to inhibit heightened platelet activity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436

Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248415609436